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Resistance to the metabolic actions of insulin is one of the salient features of impaired glucose tolerance and Type 2 diabetes mellitus (Type 2 DM). A number of prospective studies have shown that the development of insulin resistance is an early event in the natural progression of the disease. 1, 2) Thus, drugs that reverse the onset of insulin resistance fulfill a major medical need for the treatment of Type 2 DM.
3) Insulin resistance is characterized by the impaired uptake and utilization of glucose in insulin-sensitive target organs such as adipocytes and skeletal muscle and by the impaired inhibition of hepatic glucose output. [4] [5] [6] Thiazolidinediones are a class of oral insulin-sensitizing agents that improve glucose utilization without stimulating insulin release. They significantly reduce glucose, lipid, and insulin levels in rodent models of Type 2 DM and obesity, [7] [8] [9] and recent clinical data support their efficacy in obese diabetic patients.
10) The discovery of compounds which improve insulin resistance enables the continued treatment of Type 2 DM patients without inducing hypoglycemia. Clofibrate is the first such compound found to improve insulin resistance. 11, 12) It was followed by the discovery of thiazolidinedione compounds, typically represented by ciglitazone. [13] [14] [15] Of the thiazolidinedione compounds, ciglitazone (A), troglitazone (B), [16] [17] [18] englitazone (C), 19) pioglitazone (D), 20) and rosiglitazone (E) 21) are potential antidiabetic compounds that have been clinically examined.
Scientists at Glaxo identified rosiglitazone as the first high-affinity ligand for peroxisome proliferator-activated receptor g (PPARg), a receptor subtype selectively expressed in adipocytes and shown to induce adipocyte differentiation. [22] [23] [24] These studies are predicting the thiazolidinedione compounds to be promising compounds, capable of ameliorating Type 2 DM by improving insulin resistance without inducing hypoglycemia. Troglitazone is the first of a novel class of compounds, the thiazolidinedione derivatives, to reach clinical practice. Troglitazone induces preadipocyte differentiation, probably via PPAR g receptors. 25) While it is not clear whether the antihyperglycemic mechanism requires preadipocyte differentiation, the maximum glucose-lowering effect (about 40 mg/dl) of troglitazone is similar to that seen with metformin. Thiazolidinediones have been shown to improve insulin sensitivity/glucose utilization in animal model and to enhance insulin sensitivity in human. [26] [27] [28] [29] But, it was assumed that troglitazone has the hepatotoxicity [30] [31] [32] due to the enterohepatic circulation of the metabolites, that is quinone moiety.
In order to prevent this and to discover novel compounds which have the ability to increase glucose utilization, we focused our attention on the modification of chroman moiety to erythrose, ribose and substituted pyrrolidine group. As a result of our efforts, in this paper, we describe the synthesis and the in vitro glucose utilization activity. Since we found that the compounds 24a and 24b, having a O-protected Nbenzyl pyrrolidine group involving thiazolidinedione moiety, showed an excellent glucose utilization activity in L6 myocytes (Table 1) , our subsequent research will be focused on the antihyperglycemic activity of these compounds in vivo.
Chemistry
Several erythrose, ribose and substituted pyrrolidine-containing thiazolidinediones were prepared. A general synthetic route is shown in Chart 1. First, synthesis of the protected erythrose-containing thiazolidinedione compound 5 was carried out by the Knoevenagel's condensation 33) of a key intermediate aldehyde 3 with 2,4-thiazolidinedione and desired compound 7 also was obtained from 3 by deprotection, benzylation of erythrose group and condensation procedure as shown in Chart 1 respectively.
Desired compounds 8 and 6 were prepared by condensation and reduction with 20% Pd(OH) 2 under hydrogen atmosphere. Treatment of the D-erythrono-r-lactol under the Wittig's condition with phosphonium ylide generated the erythrose ethyl ester 1 which were reduced into the erythrose alcohol compound 2 by reduction. Synthesis of the key intermediate aldehyde 3 was carried out by the Mitsunobu's condition 34, 35) as shown in Chart 2. The erythrose naphthylmethylene thiazolidinedione 12 was synthesized as shown in Chart 3. Mitsunobu's condition of the alcohol 2 with 6-hydroxy-2-naphtoic acid ethyl ester gave naphthyl ethyl ester compound 9, which were transformed into the desired erythrose naphthylmethylene thiazolidinedione 12 via catalytic hydrogenation with 20% Pd(OH) 2 of the unsaturated naphthylmethylene thiazolidinedione 11 by the same procedure above described for the Knoevenagel's condition (Chart 3).
Synthesis of O-protected ribose benzylidene thiazolidinediones 17a, b (Chart 4) were carried out via the Wittig reaction, reduction, Mitsunobu reaction, and condensation from the starting materials 13a, b through the same procedure as describe in Chart 2. Unsaturated O-protected N-benzyl pyrrolidine derivatives 22 and 24a, b (Chart 5) were derived from the benzylation of the O-protected pyrrolidine ethyl ester (18) by using the general procedures described in Charts 2-4.
N-Alkyl pyrrolidine benzylidene analogues 31a-c (Chart 6) were synthesized by the similar procedure described in Chart 5. Benzoylation of 20, followed by deprotection, Oalkylation and removal of the N-benzyl group by treatment with 20% Pd(OH) 2 at hydrogen atmosphere produced compound 27. The aldehyde compounds 30a-c were prepared by Mitsunobu reaction via reductive alkylation of 27 with para-formaldehyde, propionaldehyde or cyclopentanone in the presence of sodium cyanoborohydride which was con- verted into the benzylidene thiazolidinediones 31a-c by the Knoevenagel condition. N-alkyl pyrrolidine benzyl derivatives 32a-c were prepared by catalytic hydrogenation of 31a-c in Chart 6.
N-Protected naphthalene-containing pyrrolidine derivatives (36a, b) (Chart 7) were prepared by using the general procedures described in Chart 7.
Results and Discussion
Several thiazolidinedione derivatives, represented by compounds A-E (Chart 1) described above, have been reported to possess very good antihyperglycemic activity. Of these compounds, troglitazone was found to prevent the inhibitory effect of inflammatory cytokines such as TNF-a, which induce peripheral insulin resistance in glucose uptake in insulin-induced adipocyte differentiation of 3T3-L1 cells. 36) Troglitazone (B) is reported to have the potent agonism to PPARg and a good antihyperglycemic effect in genetically diabetic ob/ob mice. 37) Considering the structure of troglitazone (B), we designed and synthesized erythrose, ribose, and substituted pyrrolidine thiazolidinedione derivatives with a nitrogen or oxygen containing 5-membered ring system at the lipophilic moiety as shown in Chart 8.
Erythrose, ribose and substituted pyrrolidine thiazolidinediones 5, 8, 17, and 24 designed by troglitazone structure having a fused chromane ring open via routes I, and II, respectively, were synthesized and evaluated for their glucose utilization in L6 myocytes assay in vitro. First of all, in order to examine the effect of pharmacophore head site, two different type erythrose-containing compounds 5 and 8 were synthesized, that is, the thiazolidinedione or malonate group and evaluated their activity. Almost erythrose compounds having a thiazolidinedione moiety 5, 7, 11, and 12, except for malonate-containing erythrose compounds 6, and 8, showed better glucose utilization in L6 myocytes assay than rosiglitazone (Table 1 ). These data suggest that a pharmacophore of a erythrose ring with a thiazolidinedione group is required for in vitro activity.
Considering these results, the ribose derivatives 17a, b containing the bulky aromatic group were synthesized and examined their activity in L6 myocytes. The results revealed that the ribose derivative containing benzylidene compound 17a showed an excellent glucose utilization activity than rosiglitazone and troglitazone as shown in Table 1 , but tricyclic ribose having a spiro-cyclohexylidene dioxol compound 17b exhibited a reduced activity than reference compounds in L6 myocytes. To explore the effect of the orientation and proximity of the substituent, the oxygen atom of the erythrose or ribose group replaced by the nitrogen atom. As a consequence, several substituted pyrrolidine containing benzylidene or benzyl thiazolidinedione derivatives 24a, b, 31a-c, 32a-c, 35a, b and 36a, b were prepared and the results are shown in Table 1 . The substituent on the nitrogen at the 1-position of the pyrrolidine ring was varied. Among these synthesized compounds, benzyl substituted pyrrolidine derivatives 24a, b, and 36a showed the excellent glucose utilization than reference compounds in L6 myocytes cell assay. But the N-methyl, N-propyl or N-benzyl substituted pyrrolidine derivatives 31a, b, 32a, b, 35a, b and 36b exhibited reduced glucose utilization activity. Compared with phenyltethered thiazolidinediones 24a, b and naphthylmethylenetethered thiazolidinediones 35a, b, naphthylmethylene-tethered thiazolidinedione 35a, b showed reduced glucose utilization activity. Reduction of unsaturated thaizolidinediones 35a, b to saturated thiazolidinediones 36a, b results in dramatic increase of glucose utilization activity as shown in Table 1 . As a result of these studies, the substituted pyrrolidine derivatives 24a, b, and 36a exhibited not only the better activity in enhancing glucose utilization activity in L6 myocytes but also had better safety index than rosiglitazone and troglitazone.
In conclusion, on the basis of both in vitro glucose utilization activity and preliminary toxicity evaluation, 5-{4-[2-(1-benzyl-3,4-bis-benzyloxypyrrolidin-2-yl)ethoxy]benzylidene}thiazolidine-2,4-dione (24b) was selected for further evaluation and is presently under pharmacological studies.
Experimental
All reactions were conducted under anhydrous condition in solvents dried over molecular sieves type 4 Å under nitrogen atmosphere and performed using oven dried glassware. Melting points were determined on a Buchi 510 capillary apparatus and are uncorrected. IR spectra were recorded on a Bruker Vector 22 FT-IR spectrometer. NMR spectra were recorded on a Bruker DPX 400 MHz instrument operating at 400 MHz for proton and 100 MHz for carbon NMR and were performed in DMSO-d 6 solutions using tetramethylsilane as the internal reference except where indicated otherwise. The coupling constants (J) are reported in Hz. Mass spectra were recorded on a HP 5989B instrument. Flash chromatography was performed using Merck silica gel 60 (230-400 mesh) according to the published procedure. 61 mmol) in dry dichloromethane (100 ml) at Ϫ78°C was added DIBAL-H (1.0 M in CH 2 Cl 2 , 40 ml, 40 mmol) by syringe pump under N 2 atmosphere at the same temperature. After stirring for 1 h, the reaction mixture was quenched with methanol (10 ml), and stirred at room temperature for 1 h. Rochelle's solution (100 ml) was added gradually to the vigorously stirred the reaction mixture and stirred overnight. The organic layer was separated and washed with water, brine, respectively, and dried (MgSO 4 ), and the filtrate was concentrated by evaporation under reduced pressure. The obtained residue and ethoxycarbonyl ethylidene triphenylphosphorane (17 g, 46.95 mmol) was dissolved in toluene (150 ml), and the resulting mixture was stirred at 110°C for 24 h. The reaction mixture was cooled at room temperature, and was cyclized by the addition of potassium tert-butoxide (3.5 g, 31.61 mmol) and was stirred for 3 h, and quenched with saturated NH 4 
4-[2-(2,2-Dimethyltetrahydrofuro[3,4-d ][1,3]dioxol-4-yl)propoxy]benzaldehyde (3)
An ice-cooled solution of diethyl azodicarboxylate (DEAD, 0.5 ml, 3.11 mmol) in tetrahydrofuran (THF, 30 ml) was treated with the title alcohol compound 2 (525 mg, 2.59 mmol) for 15 min, and then 4-hydroxybenzaldehyde (412 mg, 3.37 mmol), and triphenyl phosphine (Ph 3 P, 817 mg, 3.11 mmol) were added to the mixture. The resultant was stirred at icecooled temperature for 30 min, and then allowed to warm to room temperature overnight. The mixture was quenched with saturated NH 4 OH (20 ml) and extracted with EtOAc. The organic layer was washed with water, dried 
4-[2-(3,4-Dihydroxytetrahydrofuran-2-yl)propoxy]benzaldehyde (4)
propoxy]benzaldehyde (3) (2.33 g, 7.6 mmol) in trifluoroacetic acid-H 2 O (4 : 1, v/v) was stirred at room temperature for 24 h. The reaction mixture was poured into water (60 ml) and extracted with EtOAc (3ϫ100 ml). The extract was washed with water, dried (MgSO 4 ), and concentrated in vacuo to leave an oil which was purified by column chromatography on SiO 2 with nhexane-EtOAc (4 : 1, v/v) to give the title compound 4 as an oil (723 
2-{4-[2-(2,2-Dimethyltetrahydrofuro[3,4-d ][1,3]dioxol-4-yl)propoxy]-benzaldehyde}malonic Acid Diethyl Ester (6)
A mixture of a aldehyde compound 4 (300 mg, 1.02 mmol), diethylmalonate (0.18 ml, 1.23 mmol), piperidine (0.12 ml, 1.23 mmol), and EtOAc (30 ml) was heated at reflux temperature through Dean-stark trap for overnight. After being cooled to room temperature, the mixture was concentrated reduced pressure. The residue was purified by column chromatography using n-hexane-EtOAc (3 : 1, v/v) to give the title compound 6 as an oil (250 mg, 54% yield 
5-{4-[2-(3-Benzyloxy-4-methyltetrahydrofuran-2-yl)propoxy]benzylidene}thiazolidine-2,4-dione (7)
To a suspension of sodium hydride (60% in mineral oil, previously washed with n-hexane, 162 mg, 4.05 mmol) in dimethylformamide (DMF) (15 ml) was added 4-[2-(3,4-dihydroxytetrahydrofuro-2-yl)propoxy]benzaldehyde (4) (360 mg, 1.35 mmol), and benzyl bromide (0.58 ml, 4.86 mmol) over N 2 atmosphere at 0°C. After stirring at room temperature for 24 h, the reaction mixture was poured into ice-water and acidified with 1 N HCl to give the product and extracted with EtOAc (100 ml). The extract was washed with water, brine, dried (MgSO 4 ), and concentrated in vacuo. The residue was dissolved in EtOH (30 ml) and added 2,4-thiazolidivedione (158 mg, 1.35 mmol), and piperidime (0.13 ml, 1.35 mmol), respectively. The reaction mixture was refluxed in a Dean-stark trap for 24 h. After cooling to room temperature, the solution was concentrated in vacuo. The residue was chromatography on SiO 2 eluted with nhexane-EtOAc (4 : 1, v/v) to give the title compound 7 as an oil (290 
propoxy]benzaldehyde}malonic acid diethyl ester (6) (70 mg, 0.15 mmol) in a mixture of methanol (10 ml) and dioxane (10 ml) was stirred in the presence of 20% palladium hydroxide on charcoal (35 mg, 50% w/w) under an atmosphere of hydrogen at room temperature until hydrogen uptake ceased. The reaction mixture was filtered through celite, and the filtrated was evaporated under a vacuum. The crude product was chromatography on SiO 2 
2-(6-Benzyloxymethyl-2,2-cyclohexyltetrahydrofuro[3,4-d ][1,3]dioxol-4-yl)propionic-1-ol (15b)
The title compound 15b (219 mg, 56% yield) was prepared as an oil from 2-(6-benzyloxymethyl-2,2-cyclohexyltetrahydrofuro [3,4- 
4-[2-(6-Benzyloxymethyl-2,2-dimetgthyltetrahydrofuro[3,4-d ][1,3]-dioxol-4-yl)propoxy]benzaldehyde (16a)
The title compound 16a (270 mg, 51% yield) was prepared as an oil from 2-(6-benzyloxymethyl-2,2-dimethyltetrahydrofuro [3,4- 05 (m, 2H), 7.31 (m, 5H), 7.85 (m, 2H), 9.91 (s, 1H) . 13 [4,5-c] pyrrol-4-yl)acetic acid ethyl ester (3.0 g, 13.08 mmol), and benzaldehyde (3.99 ml, 39.2 mmol) in methanol (30 ml) was adjusted pH 3 by acetic acid (12 ml), at 0°C, and gradually added sodium cyanoborohydride (1.23 g, 19.62 mmol), the resulting mixture was stirred at room temperature overnight, and quenched with 2 N NaOH and extracted with CH 2 Cl 2 . The extract was washed with brine, dried over MgSO 4 , and concentrated in vacuo to leave an oil which was purified by column chromatography on SiO 2 with n-hexane-EtOAc 66 (m, 2H), 7.28 (m, 5H) . 13 (20) 
5-{4-[2-(6-Benzyloxymethyl-2,2-cyclohexyltetrahydrofuro[3,4-d ][1,3]-dioxol-4-yl)propoxy]benzylidene}thiazolidine-2,4-dione (17b)

2-(2-Benzyloxyethyl)3,4-diethoxy-N-methylpyrrolidine (28a)
The title compound 28a (318 mg, 61% yield) was prepared from benzoic acid-(3,4-diethoxypyrrolidin-2-yl)ethyl ester (27) Benzyloxyethyl)3,4-diethoxy-N-cyclopentylpyrrolidine (28c 
2-(2-
